Medexus Pharmaceuticals

Medexus Pharmaceuticals MEDXF Stock

$4.00   5.820107%
Add to favorites
Market Cap
$125.70M
LOW - HIGH [24H]
$3.90 - $4.00
VOLUME [24H]
$700.00
P/E Ratio
0
Earnings per share
-$0.07
ISIN
CA58410Q2036

Medexus Pharmaceuticals Price Chart

Sorry, that's all we've gotfor now...

Medexus Pharmaceuticals (MEDXF) stock price today is 4 USD on OTC Markets OTCQX (+5.82% on the day). Updated .

Medexus Pharmaceuticals MEDXF Financial and Trading Overview

Medexus Pharmaceuticals stock price 4 USD
Previous Close 3.97 USD
Open 3.84 USD
Bid 3.78 USD x 70000
Ask 3.82 USD x 190000
Day's Range 3.78 - 3.85 USD
52 Week Range 1.8 - 4 USD
Volume 6.4K USD
Avg. Volume 10.67K USD
Market Cap 119.98M USD
Beta (5Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -0.07 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 7 USD

MEDXF Valuation Measures

Enterprise Value 137.87M USD
Trailing P/E N/A
Forward P/E -190.90001
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 1.1144649
Price/Book (mrq) 2.4711976
Enterprise Value/Revenue 1.281
Enterprise Value/EBITDA 7.915

Trading Information

Medexus Pharmaceuticals Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 90.90%
S&P500 52-Week Change 13.32%
52 Week High 4 USD
52 Week Low 1.8 USD
50-Day Moving Average 3.55 USD
200-Day Moving Average 3.07 USD

MEDXF Share Statistics

Avg. Volume (3 month) 10.67K USD
Avg. Daily Volume (10-Days) 9.07K USD
Shares Outstanding 31.43M
Float 28.83M
Short Ratio N/A
% Held by Insiders 8.01%
% Held by Institutions 3.45%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends March 31, 2026
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End March 31, 2027

Profitability

Profit Margin -1.14%
Operating Margin (ttm) 7.32%
Gross Margin 63.57%
EBITDA Margin 16.17%

Management Effectiveness

Return on Assets (ttm) 3.31%
Return on Equity (ttm) -2.45%

Income Statement

Revenue (ttm) 107.66M USD
Revenue Per Share (ttm) 3.37 USD
Quarterly Revenue Growth (yoy) 17.59%
Gross Profit (ttm) 68.45M USD
EBITDA 17.42M USD
Net Income Avi to Common (ttm) -1238000 USD
Diluted EPS (ttm) -0.07
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 8.35M USD
Total Cash Per Share (mrq) 0.27 USD
Total Debt (mrq) 26.22M USD
Total Debt/Equity (mrq) 54.02 USD
Current Ratio (mrq) 1.266
Book Value Per Share (mrq) 1.545

Cash Flow Statement

Operating Cash Flow (ttm) 16.3M USD
Levered Free Cash Flow (ttm) -11509750 USD

Profile of Medexus Pharmaceuticals

Country United States
State ON
City Toronto
Address 10 King Street East
ZIP M5C 1C3
Phone 877 422 5242
Website https://www.medexus.com
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees 90

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; and intraarticular, a triamcinolone hexacetonide injectable suspension. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.

Q&A For Medexus Pharmaceuticals Stock

What is a current MEDXF stock price?

Medexus Pharmaceuticals MEDXF stock price today per share is 4 USD.

How to purchase Medexus Pharmaceuticals stock?

You can buy MEDXF shares on the OTC Markets OTCQX exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Medexus Pharmaceuticals?

The stock symbol or ticker of Medexus Pharmaceuticals is MEDXF.

Which industry does the Medexus Pharmaceuticals company belong to?

The Medexus Pharmaceuticals industry is Drug Manufacturers - Specialty & Generic.

How many shares does Medexus Pharmaceuticals have in circulation?

The max supply of Medexus Pharmaceuticals shares is 31.43M.

What is Medexus Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Medexus Pharmaceuticals PE Ratio is now.

What was Medexus Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Medexus Pharmaceuticals EPS is -0.07 USD over the trailing 12 months.

Which sector does the Medexus Pharmaceuticals company belong to?

The Medexus Pharmaceuticals sector is Healthcare.

$2.22T
Total marketcap
$75.98B
Total volume
BTC 58.54%   •   ETH 10.00%
Dominance
Select currency